A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

As a result, mergers with larger pharma companies and alliances with academia are simply a part of that reality. And to be fair, some biotech organizations build themselves in a manner designed to ...

M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.

early-stage life sciences companies. GO Virginia approved a $14.3 million funding package to three Virginia biotech accelerator organizations in response to a multiregional proposal called “Project ...

While 2024 was a “challenging” year for biotech stocks ... such as contract research organizations (CROs), contract manufacturing organizations (CMOs), and companies that provide tools ...